Airsculpt Technologies, Inc. (AIRS) · Nov 6, 2026 · Earnings

AirSculpt earnings miss as cases plunge and guidance is cut

Miss — Revenue $31.94M vs ~$34.33M consensus

AirSculpt earnings missed expectations as cases dropped 9.6%, margins collapsed, and management cut 2026 guidance despite refinancing its debt.

AirSculpt is trying to stabilize its premium body-contouring centers while expanding into GLP-1-related procedures, after Q2 showed roughly stable same-center demand and management had guided to 2026 revenue of approximately $151–157 million and adjusted EBITDA of $12–14 million. The quarter broke that stabilization story. Revenue fell 8.7% year over year to $31.9 million, well below the published consensus of roughly $34.3 million, while cases dropped 9.6% even though revenue per case rose 2.3% (Other Data; Same-center Information). The company itself says the results were “below expectations,” and it reduced full-year guidance to reflect the weakness continuing through year-end. 〔0〕

Q3 2026Q3 2025Consensus
Revenue (Income Statement)$31.944M (-8.7%)$34.993M$34.33M
Diluted EPS (Income Statement)$(0.10)$(0.15)$(0.03)
Cases (Other Data)2,483 (-10.7%)2,780
Adjusted EBITDA (Other Data)$0.393M (-87.1%)$3.039M
Adjusted EBITDA margin (Other Data)1.2%8.7%

The problem is volume, not pricing. Revenue per case increased to $12,865, but that higher ticket could not offset fewer procedures; same-center cases were down 9.6%, and adjusted EBITDA fell to just $0.4 million from $3.0 million. That makes the GLP-1 opportunity a strategy still in rollout—not yet a demonstrated offset to weakening core demand. The filing says AirSculpt is expanding GLP-1-related procedures, but provides no quantified contribution from them. 〔1〕

The refinancing buys time, but does not repair execution. AirSculpt replaced its existing credit facility with a $39.0 million term loan maturing November 5, 2031 and retained a $5.0 million undrawn revolver, reducing near-term maturity pressure. 〔2〕 But the company also raised $7.2 million through its at-the-market offering during the quarter, so liquidity improvement came alongside additional equity issuance; operating cash flow was negative $3.5 million in Q3 (Cash Flow Data).

Bottom line: This is a clear setback to AirSculpt’s stabilization story: demand weakened sharply, profitability nearly disappeared, and guidance was cut. The longer-dated refinancing limits immediate balance-sheet pressure, but the business now needs to prove that the GLP-1 expansion can reverse falling procedure volumes—not merely broaden the offering.

What to watch next

Q4 results and updated 2026 guidance

Original filing on SEC EDGAR

More Airsculpt Technologies, Inc. news

AirSculpt earnings miss as cases plunge and guidance is cut | AIRS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.